A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untre

• Status: Not yet recruiting
• Trial end date: 2027-05-05

Summary

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combination therapy.

• Phase: Phase 1

Details

• Lead Sponsor: ADC Therapeutics S.A.
• Treatments: Cyclophosphamide; Doxorubicin; Loncastuximab tesirine; Prednisone; Rituximab; Vincristine